Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q5NX
|
|||
| Former ID |
DAP001255
|
|||
| Drug Name |
Lenalidomide
|
|||
| Synonyms |
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Approved | [1], [2], [3], [4] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Celgene Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H13N3O3
|
|||
| Canonical SMILES |
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
|
|||
| InChI |
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
|
|||
| InChIKey |
GOTYRUGSSMKFNF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 191732-72-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9372858, 12015317, 14847985, 30420059, 46505725, 47206522, 50067858, 50112744, 50484855, 53786789, 57399776, 81092908, 85174578, 91148448, 92719197, 99437218, 103222228, 109693476, 113461419, 117883377, 119509589, 124409664, 124756946, 124893327, 124893328, 125163752, 125343917, 126591352, 126628313, 126652519, 126667069, 127984536, 134338492, 134964412, 135134887, 135600354, 135610831, 135683667, 136367898, 136374703, 136949134, 137000301, 137039885, 140119412, 143496160, 144116136, 144206045, 152237735, 152258939, 160647784
|
|||
| ChEBI ID |
CHEBI:63791
|
|||
| ADReCS Drug ID | BADD_D01253 | |||
| SuperDrug ATC ID |
L04AX04
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331). | |||
| REF 2 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 3 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 5 | Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. | |||
| REF 6 | The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-99. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.